Big Pharma Fails 50% of the Time in Phase Three. AI Can Fix That | Vin Singh, BullFrog AI

The point of this is to increase likelihood that a clinical trial will succeed. Considering it takes ten to fifteen years and 1 to $2,000,000,000 to develop a drug, it's quite shocking that big pharma fails fifty percent of the time in phase three. Are you concerned about competition from Big Pharma who may be developing We discovered the biological drivers of those diseases. We believe we've discovered the genes that drive depression, bipolar, and schizophrenia from a one of a kind dataset that does not exist anywhere in the world. It seems that you would be an acquisition target by Zing pharma. Let's see if we can get one of these drug discovery AI deals done or target discovery deals done. Introduce yourself to listeners, how you got the Bullfrog. Craig, thanks for having me today. Great to be here. So, you know, my name is Vin Singh. I'm the chairman, founder, and CEO of Bullfrog AI. We are a publicly traded company under the symbol BFRG on Nasdaq. So, obviously, there are certain things I won't be able to say or questions I might not be able to answer, but looking forward to it. So, a little bit about me. I have almost thirty years of industry experience, life sciences, biotech. I'm a biomedical engineer by training. I'm a three time founder of investor backed companies. Two of them have gone public. The first company I cofounded is a company called MaxCyte, symbol is MX CT, as a cell therapy systems company. When they went public on Nasdaq several years ago, there I think the market cap was around 1,500,000,000. Obviously, biotech's been beaten down pretty hard, over that period of time. After that, I founded a company called Next Healthcare, which was at the time the world's first adult skin cell and stem cell banking company for regenerative medicine applications. And that company is still operating and doing some different things today. And then about eight years ago, I I founded Bullfrog. And, the reason I founded the company was I I was, you know, very surprised by the high failure rates in late stage clinical development. And, you know, considering it takes ten to fifteen years and 1 to $2,000,000,000 to develop a drug, it's, quite shocking that big pharma fails fifty percent of the time in phase three. It doesn't it didn't make sense to me. And I also realized if I could make a difference, there's a lot of people that will benefit from drugs that maybe otherwise wouldn't. And I think, the trickle down effect would be, you know, drugs would be more affordable in general, if you have more success. Right? Because somebody's paying for all those failures. Right? And it's unfortunately, it's the health care system that's paying for it. So, you know, I started the company and that the the original focus was why don't we try to rescue failed drugs because there's like a ocean of them out there. …